Introduction: Shoulder pain and disability are well-documented sequelae of breast cancer treatment. Angiogenesis signaling may have a role in the development of shoulder pain or shoulder disability in breast cancer survivors. The aim of this study was to determine if polymorphisms in angiogenesis-related genes are associated with shoulder pain or disability following breast cancer treatment. Participants and methods: A cross-sectional study was conducted on 220 South African breast cancer survivors. The study aimed to evaluate associations between shoulder pain/ disability and seven single nucleotide polymorphisms (SNPs) within five angiogenesisassociated genes: KDR (rs2305948 C>T; rs7667298 C>T), NOS3 (rs1549758 C>T), MMP2 (rs708269 A>T), THBS2 (rs9766678 A>G) and TIMP3 (rs5754312 T>A; rs715572 G>A). In addition, associations between shoulder pain/disability and inferred haplotypes for KDR and TIMP3 SNPs were evaluated. Participants were grouped into no-low and moderate-high shoulder pain/disability based on total pain/disability scores: ≤30 and >30, respectively using the shoulder pain and disability index (SPADI). Results: No independent associations with shoulder pain/disability categories were found for all SNPs. However, 1 inferred haplotype (KDR "TT") differed significantly (P=0.014) between the shoulder disability categories. After adjusting for participants' age, the differences in KDR inferred haplotype frequencies between shoulder disability categories became non-significant (P=0.052). Conclusion: Our findings provide a preliminary suggestion of a possible association between polymorphisms in genes involved in angiogenesis and the presence of moderatehigh shoulder disability among South African breast cancer survivors. A larger prospective cohort study is currently being conducted by our group.
Introduction
Shoulder pain and disability are well-known consequences of conventional breast cancer treatment. [1] [2] [3] [4] [5] [6] [7] Such morbidities may persist long after the recovery period for breast cancer treatment 3, 4, 7 and have been associated with reduced quality of life. 1, 8, 9 Prevalence rates of up to 68% have been reported for shoulder pain or disability beyond 6 months after primary treatment although they vary widely. [3] [4] [5] [6] 10, 11 The complex etiology of breast cancer treatment-related shoulder pain and disability has long been appreciated and several risk factors have been identified including: treatment type, time after treatment, disease characteristics, age, genetic factors and the presence of co-morbidities. 2, 6, 12, 13 However, a large proportion of variability in the development of morbidity after breast cancer treatment still remains unexplained. 12, 14 Previous findings suggest that shoulder morbidity after breast cancer treatment is bilateral 2, 10, 15 and it has been shown that structures unrelated to direct surgery and/or radiotherapy treatment are affected, 16 suggesting a systemic cause. These findings substantiate the need to explore the potential involvement of molecular signaling pathways. Several molecular signaling pathways have been implicated in non-cancer shoulder complex morbidity including but not limited to angiogenesis, extracellular matrix (ECM) remodeling and apoptosis. [17] [18] [19] [20] [21] [22] [23] [24] [25] Such studies, investigating the role of molecular pathways, included connective tissue conditions of the shoulder such as tendon injuries or tendinopathy and rotator cuff disease (RCD). 26 Angiogenesis appears to be particularly important in shoulder complex morbidity in healing and adaption pathways. Its signaling can induce ECM remodeling and nitric oxide synthase (NOS) activity. 27, 28 NOS activity has been shown to be upregulated in rotator cuff tendon injury and may play a role in the healing process. [29] [30] [31] Hypoxia-inducible factor 1α (HIF-1α), a pro-angiogenic transcription factor, is elevated in rotator cuff pathology (including impingement, tendinopathy or tears). 25 Although non-cancer shoulder conditions have a different etiology, the altered shoulder movement patterns observed in breast cancer survivors mimic those seen in known general shoulder conditions such as rotator cuff disease and adhesive capsulitis. 7 In fact, such diagnoses have been used to describe shoulder-complex morbidities in breast cancer survivors and have strongly been associated with pain. [32] [33] [34] Studies evaluating the role of molecular signaling pathways in breast cancer treatmentrelated morbidity have largely focused on the inflammatory pathway. 26 Evaluation of signaling factors involved in angiogenesis, ECM remodeling or apoptosis in breast cancer survivors may, therefore, increase our understanding of the pathophysiology, and contribute towards an explanation of the individual variability in the development, of shoulder pain and disability.
There is a lack of relevant studies investigating the role of angiogenesis, ECM remodeling and NOS activity in the development of shoulder pain and disability after breast cancer treatment. Previous studies evaluating gene expression profiles or genetic associations, in the context of morbidity following breast cancer treatment, have largely focused on inflammatory factors with a few exceptions. 26 Such studies did not focus, specifically, on shoulder pain/disability as a clinical end-point. 26 ECM remodeling and NOS activity are important events in angiogenesis signaling. Angiogenesis signaling through KDR (Kinase Insert Domain Receptor), its main signaling receptor, activates ECM remodeling factors such as MMPs (matrix metalloproteinases), and eNOS (endothelial NOS). 35, 36 The activity of KDR can be regulated by inhibitors such as thrombospondins (THBSs) while the activity of MMPs can be regulated by TIMPs (tissue inhibitor of MMPs). 37, 38 We hypothesize that shoulder pain or disability after breast cancer treatment may be associated with polymorphisms in genes involved in angiogenesis, ECM remodeling or NOS activity. The aim of this study, therefore, was to correlate DNA sequence variants of key angiogenesis-related signaling factors, including genes involved in ECM remodeling and NOS activity: KDR, MMP2, NOS3, THBS2, TIMP3, with the occurrence of shoulder pain or shoulder disability among female breast cancer survivors.
Methods

Study design
This is a pilot, cross-sectional study including a genetic association component. This study is a sub-study of a larger on-going project which seeks to correlate clinical disease state of the shoulder after breast cancer treatment with biomarkers of inflammation, fibrosis and angiogenesis, including their associated genetic variants.
Participants and setting
Study participants were recruited in the period August 2013 to July 2015, and relevant information regarding the study was provided upon recruitment. Participants, all women, were conveniently recruited from the waiting room of the Oncology Clinic of a tertiary public teaching hospital in South Africa. Although women of all races were recruited, only the larger "mixed-ancestry" ethnic group (Mixed-ancestry group: n=243, Black: n=43, White: n=22) was used for analysis to avoid confounding. The mixed-ancestry ethnic group, from the Western Cape region of South Africa, used in our study is composed of populations who self-identify as "Coloured." This is a unique group with a rich genetic admixture ancestrally derived from immigrants from Western Europe, West Africa, Asia and the indigenous Southern African populations. All participants agreeing to participate gave written informed consent and were included on the basis of defined inclusion and exclusion criteria (Table 1) . 40, 41 Using the SPADI, participants rated movement-related pain and difficulty associated with specific activities of daily living on a scale of 0 (no pain/difficulty) -10 (extreme pain/difficulty). The pain subscale of the SPADI has 5 items whereas the disability subscale has 8 items. However, both scales are reported as percentages of possible total scores. For each subscale, the total score was divided by the number of completed items and expressed as a percentage.
Study procedures
Variables of interest
The primary outcome measure in this study was the shoulder pain and disability index (SPADI). Pain and disability scores were categorized into no -low pain/disability and moderatehigh pain/disability based on total pain or disability scores ≤30 and >30, respectively. The development of these categories was based on reported SPADI score effects on activities of daily living 42 and reported clinical relevance of SPADI scores. 40 Exposures in this study are bi-allelic SNP genotypes from 5 candidate genes: KDR (VEGF-R2) (rs2305948 C>T; rs7667298 C>T), NOS3 (rs1549758 C>T), MMP2 (rs708269 A>T), THBS2 (rs9766678 A>G) and TIMP3 (rs5754312 T>A; rs715572 G>A). Potential covariates evaluated for association included participants' age at consent, time after surgery, type of surgery, extent of lymph node surgery, number of lymph nodes removed, tumor grade and adjuvant therapy type.
Single nucleotide polymorphism selection
SNPs within genes involved in the angiogenesis signaling pathway were selected for analysis. 
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were also included in every plate. Samples were considered successfully genotyped unless they failed twice to amplify for a particular SNP assay. More than 99% of all samples were successfully genotyped for each SNP (only 1 out of 220 samples were unsuccessfully genotyped for each of NOS3 rs1549758, MMP2 rs708269 and THBS2 rs9766678. Data generated from the assays were analyzed using Thermo Fisher Cloud genotyping analysis Software Version: 3.3.0-SR2-build 21 and genotypes were automatically called.
inferred haplotype construction
KDR and TIMP3 haplotype pairs were inferred using the genotypes at rs2305948 C>T and rs7667298 C>T, and rs715572 G>A and rs5754312 T>A, respectively. A low haplotype frequency cut-off of 4% was used to avoid unreliable results.
Bias
Just under 10% (n=23, out of a total n=243) of participants could not provide bloodbecause they were lost after consent due to the need for further medical examination in the clinic. There could potentially be differences between participants who provided blood and those who did not. However, this is unlikely, as all participants approached consented.
Sample size
Assuming expected average baseline risks of 32% and 25% for shoulder pain and disability, respectively, calculated from previous reports, 3, 4, 6, 9, [43] [44] [45] [46] [47] [48] sample size of 220 is likely sufficient to detect odds ratios of 2.0 and greater, at 80% power for allele frequencies of ≥0.2 for the log-additive genetic model (Table S2 ). For the same log-additive genetic model, our sample size is also sufficient to detect odds ratios of 2.5 for allele frequencies ≥0.15 (Table S2) . However, for the dominant genetic model, our sample size is only sufficient to detect odds ratios of 2.5 for allele frequencies ≥0.15 (Table S2) . Furthermore, our sample size is underpowered for the recessive genetic model for effect sizes of 1.5-2.5 odds ratios, and allele frequencies of 0.15-0.5. Sample size was calculated using QUANTO version 1.2.4.
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Statistical analysis
Demographic and clinical data were analyzed using Statistica Version 13. 52 Haplotypes were inferred using the R package haplo.stats. 53, 54 Logistic regression analyses were performed using SNPassoc Version 1.9-2 to evaluate the association between genotypic characteristics and pain and disability category membership. 55 Significant covariates among clinical and demographic characteristics were included in the final multivariate regression analyses. The regression models were evaluated using package "modEvA" version 1. Similarly, no significant differences (P>0.05) were noted between the no-low and moderate-high shoulder disability categories for the number of nodes removed, side of primary cancer, tumour grade, type of surgery, extent of lymph node surgery and receipt of adjuvant chemotherapy, hormonal therapy (and hormonal regimen) or radiation therapy (Table 3) . However, participants in the no-low shoulder disability category were significantly (P=0.016) older (59.1±9.1) compared with those in the moderate-high disability category (55.2±10.9). No significant differences (P>0.05) were noted between shoulder pain categories, and shoulder disability categories for radiotherapy field and adjuvant chemotherapy regimen (Tables S1 and S2 ).
Logistic regression analyses for participants' age
In the regression analysis of participants' age as a predictor for shoulder pain, the odds of being in the moderate-high shoulder pain category decreased significantly for older participants (OR 0.94, 95% CI: 0.91,0.97; P<0.001) ( Table 4) . This means that older participants had lower odds, while younger participants had higher odds, of reporting moderate-high shoulder pain. The regression model predicted 5.2% of the variance in shoulder pain category membership.
In the regression analysis of participants' age as a predictor for shoulder disability, the odds of being in the moderate-high shoulder disability category decreased significantly for older participants (OR 0.96, 95% CI: 0.93,0.99; P=0.017) ( Table 5 ). This means that older participants had lower odds, while younger participants had higher odds of reporting moderate-high shoulder disability. The regression model predicted 2.5% of the variance in shoulder disability category membership.
Genotype/allele frequency distributions between shoulder pain/disability categories
For both shoulder pain and shoulder disability, no significant differences in the genotype/allele frequency distributions were noted between the no -low and moderate-high categories for all SNPs: KDR (VEGF-R2) (rs2305948 C>T; rs7667298 C>T), NOS3 (rs1549758 C>T), MMP2 (rs708269 A>T), THBS2 (rs9766678 A>G) and TIMP3 (rs5754312 T>A; rs715572 G>A) (Tables 6 and 7 ). The genotype distributions for the no-low category for both shoulder pain and shoulder disability were in HWE for all SNPs (P>0.05) ( Tables 6 and 7) . The genotype distributions for the moderate-high category for both shoulder pain and shoulder disability were also in HWE for all SNPs (P>0.05), although the P-values for rs7667298 and rs9766678 were <0.10. (Tables 6 and 7) .
KDR and TIMP3 inferred haplotype frequency distributions between shoulder pain/disability categories
There were no significant differences in the frequency distribution of the inferred KDR haplotypes between the no-low and moderate-high shoulder pain categories (P>0.05) (Table 8 ). However, the frequencies of the inferred KDR haplotypes differed significantly between the no -low and moderate-high shoulder disability categories (P=0.024)( Table 9 ). In particular, the KDR "TT" inferred haplotype was significantly overrepresented in the no -low shoulder disability category relative to the moderate -high disability category (P=0.014, 11.4% vs 0.0%) ( Table 9 and Figure 1 ).
There were no significant differences in the frequency distribution of the inferred TIMP3 haplotypes between the no-low and moderate-high shoulder pain categories (P>0.05) ( Table 8) . Similarly, there were no significant differences in the frequency distribution of the inferred TIMP3 haplotypes between the no-low and moderatehigh shoulder disability categories (P>0.05) ( Table 9 ).
Bivariate regression analysis for inferred KDR haplotypes to predict shoulder disability including participants' age After adjusting for age, only a trend (P=0.052) was observed in the distribution of inferred KDR haplotypes between shoulder disability categories (Table 10 ). In the regression analysis for inferred KDR haplotypes, each dose of the "TT" haplotype increased the odds of being in the no-low shoulder disability category by 100% (OR: 0.00, P=0.014) ( Table 10 ).
Discussion
Our study suggests an association between functional polymorphisms within KDR and shoulder disability following breast cancer treatment among mixed ancestry individuals. Although the independent KDR SNPs were not significantly associated with shoulder disability, inferred haplotypes have implicated a genomic interval within KDR to be associated with shoulder disability. 57 Such an effect is especially important considering that both SNPs are functional 58, 59 and one of the SNPs has previously been implicated in other forms of connective tissue pathology susceptibility. 18 To the best of our 
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KDR rs2305948 C>T -rs7667298 C>T inferred haplotypes Figure 1 The frequency distribution of the KDR (rs2305948 C>T-rs7667298 C>T) inferred haplotype between no-low and moderate-high disability participants. Frequency distribution of inferred haplotypes constructed from the rs2305948 (C>T) and rs7667298 (C>T) variants in the no -low and moderate -high disability groups. Significant differences in haplotype frequencies between groups are depicted on the graph, with non-adjusted P-values. The number of participants (n) in each group is in parentheses.
knowledge, this study is the first to evaluate associations between polymorphisms in genes involved in angiogenesis and shoulder pain/disability in breast cancer survivors.
In the bivariate analyses of clinical and demographic data, only participants' age at consent was significantly associated with both shoulder pain and shoulder disability following breast cancer treatment. This association is consistent with previous reports on age and persistent pain following breast cancer treatment 12, 60, 61 . The bivariate regression models for shoulder pain or disability explained only 5.2% and 2.5% of the variance in pain or disability category membership, respectively (Tables 3 and 4 ). Contrary to previous reports, 12,62 adjuvant radiotherapy was not significantly associated with shoulder pain or shoulder disability in our study. This may reflect changes in the etiology of shoulder pain and disability with long follow-up periods, which in our cohort was >3 years on average (Tables 1 and 2 ). Furthermore, a trend contrary to previous reports, 2,5,10,46 of higher frequency of the more aggressive mastectomy compared to the conservative wide local excision (WLE) among shoulder pain controls was noted in our study. This finding may perhaps be specific to our cohort or primary outcomes: shoulder pain and shoulder disability. As with other studies, 12,14 however, our demographic and clinical data suggest that variability in the occurrence of shoulder pain or shoulder disability is not largely explained by factors related to surgical management or adjuvant treatment. Angiogenesis signaling has links to molecular signaling pathways that are important in shoulder complex pathology such as the inflammatory pathway, fibrogenesis and ECM remodeling. 27, 28 The inflammatory pathway has potent nociceptive effects which may contribute to shoulder pain. 27, 63, 64 In addition, aberrant ECM production or fibrosis can potentially contribute to stiffness in the shoulder joint capsule which can lead to reductions in range of motion. 65 Our findings support the body of evidence implicating the angiogenesis pathway in non-cancer musculoskeletal conditions such as tendon injuries or tendinopathy 17, 18 and rotator cuff disease (RCD). 19, 20 Our findings suggest that the "TT" haplotype for KDR rs2305948 C>T-rs7667298 C>T may have a protective effect on the occurrence of shoulder disability following breast cancer treatment. This haplotype was completely absent among moderate-high shoulder disability participants (Table 10 and Figure  1 ). KDR encodes VEGF-R2, the main angiogenesis signaling receptor that mediates endothelial cell survival, activation, proliferation and migration. 27, 28 Both
SNPs for the KDR "TT" haplotype have been associated with coronary heart disease 66 and notably, rs2305948 "T" allele has been associated with reduced tendinopathy risk. 18 KDR rs2305948 is a missense variant (Δ amino acid -valine/isoleucine) which has been proposed to be functional. 58 Although both amino acids are non-polar, the Isoleucine variant ("T" allele for rs2305948) has been reported to reduce VEGF-A binding efficiency. 58 Interestingly, the "TT" genotype of rs7667298 has been shown to increase KDR expression. 59 However, the biological functional significance of this haplotype on the angiogenesis pathway remains unclear. Based on the previous functional evidence, 58, 59 we suggest that this "TT" haplotype may be indicating a pro-angiogenic profile. It can also be argued that the SNPs implicated in this haplotype could be in LD to other SNPs that may underlie the occurrence of shoulder disability. The frequency of the "T" allele for both KDR SNPs was lower for the moderate-high shoulder disability category compared to the no-low category although this difference did not approach statistical significance (Table 7) . The pathophysiology that underlies shoulder disability after breast cancer treatment may be different from that which characterizes non-cancer shoulder conditions. Unlike rotator cuff disease and rotator cuff tendinopathy which are characterized by foreshortening of the pectoral girdle muscles and soft tissues, and weakening or degeneration of tendon structure, respectively, shoulder disability in our patient group could be a result of soft tissue fibrosis. 34,67 KDR signaling through VEGF-A up-regulates MMPs which in turn may alter, and perhaps weaken, tendon structure leading to movement dysfunction. Our study was not without limitations. Firstly, the sample size is small and underpowered (power <80%) for small effect sizes (OR=1.5) except for allele frequencies ≥0.40 (Table S3 and S4). Larger sample sizes may detect significant differences in other clinical and genotypic characteristics included in this study. Secondly, no direct measurements of protein or DNA expression were performed to provide additional data on the mechanisms that underlie the development of shoulder pain/disability. Thirdly, there was no wide score gap separating the two shoulder pain/disability categories. Therefore, close to the boundary score of 30, some individuals with similar shoulder pain/disability characteristics may be in different pain/disability categories. Future studies focusing on extreme phenotypes may increase effect sizes of these associations. Finally, ethnicity was determined by self-report which is less reliable than genomic estimates and therefore, there is a possibility of undetermined population stratification in our sample.
In conclusion, our findings provide preliminary evidence of an association between polymorphisms in genes involved in angiogenesis and the occurrence of shoulder disability in women following breast cancer treatment. Future studies in independent populations with larger sample sizes are warranted to further characterize the observations and explore the potential biological mechanisms.
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